An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

被引：3
|
作者：
Kabbinavar, Fairooz F.
Zomorodian, Nazy
Rettig, Matthew
Khan, Faraz
Greenwald, Daniel Reif
DiCarlo, Brian
Davidson, Sheldon J.
Patel, Ravindranath
Pandit, Lalita
Chandraratna, Rosh
Sanders, Martin
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA
[2] VA Greater Los Angeles Healthcare Syst, Dept Med, West Los Angeles, CA USA
[3] Tanslat Res Oncol US, Los Angeles, CA USA
[4] Translat Oncol Res Int, Santa Maria, CA USA
[5] Lalita Pandit MD Inc, Fountain Valley, CA USA
[6] Therapeut Inc, Santa Ana, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Alejo Rodriguez-Vida
    Pablo Maroto
    Albert Font
    Cristina Martin
    Begoña Mellado
    Alex Corbera
    Mayra Orrillo
    Oscar Reig
    Rosa Querol
    Alejandro Rios-Hoyo
    Laia Cano
    Judith Alonso
    Gemma Martinez
    Susana Galtes
    Alvaro Taus
    Maria Martinez-Garcia
    Nuria Juanpere
    Oscar Juan
    Joaquim Bellmunt
    British Journal of Cancer, 2023, 128 : 21 - 29
  • [42] Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).
    Morgans, Alicia Katherine
    Graves, Amy J.
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    Jain, Lokesh
    Gulley, James L.
    Arlen, Philip M.
    Wright, John J.
    Steinberg, Seth M.
    Draper, David
    Venitz, Juergen
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2009, 103 (12) : 1636 - 1640
  • [44] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Rodriguez-Vida, Alejo
    Maroto, Pablo
    Font, Albert
    Martin, Cristina
    Mellado, Begona
    Corbera, Alex
    Orrillo, Mayra
    Reig, Oscar
    Querol, Rosa
    Rios-Hoyo, Alejandro
    Cano, Laia
    Alonso, Judith
    Martinez, Gemma
    Galtes, Susana
    Taus, Alvaro
    Martinez-Garcia, Maria
    Juanpere, Nuria
    Juan, Oscar
    Bellmunt, Joaquim
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
  • [45] Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).
    Sher, Amna Falak
    Bruce, Justine Yang
    Gabrail, Nashat Y.
    Anderson, Ian Churchill
    Patrikidou, Anna
    Sanborn, Rachel E.
    Cho, Jae Yong
    Lee, Arielle Shebay
    Lee, Jong-Seok
    Nott, Louise M.
    Oh, Do-Youn
    Oh, Sang Cheul
    Oh, Sung Yong
    Wang Yinghui
    Wang Zejing
    Guthrie, Troy H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] 177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
    Hofman, Michael
    Emmett, Louise
    Iravani, Amir
    Sandhu, Shahneen
    Joshua, Anthony
    Pattison, David
    Goh, Jeffrey
    Kirkwood, Ian
    Tan, Thean Hsiang
    Francis, Roslyn
    Ng, Siobhan
    Rutherford, Natalie
    Gedye, Craig
    Scott, Andrew
    Lee, Sze-Ting
    Weickhardt, Andrew
    Ramdave, Shakher
    Kwan, Edmond
    Azad, Arun
    Macdonald, William
    Redfern, Andrew
    Zhang, Alison
    Stockler, Martin
    Martin, Andrew
    Davis, Ian
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [47] Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
    Miyake, Hideaki
    Kakei, Yasumasa
    Nakano, Yuzo
    Terakawa, Tomoaki
    Miyakoda, Keiko
    Harada, Kenichi
    Fujisawa, Masato
    BMJ OPEN, 2023, 13 (03):
  • [48] Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study
    Philippou, Yiannis
    Protheroe, Andrew S.
    Bryant, Richard J.
    EUROPEAN UROLOGY, 2020, 77 (06) : 759 - 760
  • [49] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    LANCET, 2010, 376 (9747): : 1147 - 1154
  • [50] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
12345